Luxembourg

Article 1 of the Loi du 4 juillet 1973 concernant le régime de la pharmacie says it directly: La pharmacie est un service public qui est géré selon le mode de la concession. No pharmacy may be established without government authorisation, taken after the opinion of the collège médical and the local authority, and the act of concession fixes an annual royalty to the Treasury of up to 2% of turnover.

Article 2 is the provision that settles the ownership question: Les concessions de pharmacie s’éteignent au plus tard au moment où le concessionnaire aura atteint l’âge de soixante-dix ans ou à la mort du concessionnaire. A concession ends at seventy or at death. A surviving spouse or dependent descendants get at most a two-year extension, after which the pharmacy must be served by a qualified Luxembourg pharmacist. Article 3 requires an incoming titulaire, if the outgoing rightholders ask, to buy the installations and stock, with disputes settled by three pharmacist arbitrators and no appeal, and bars a concessionaire from applying for another concession until they have run the current one for two years.

A legal person has neither an age nor a death. The statute is built around a natural person from beginning to end. On the enacted text, a company cannot hold a Luxembourg pharmacy concession.

One honest caveat: what was read is the original 1973 Journal officiel text. Consolidated versions were unavailable, so it could not be verified that articles 1 to 3 remain unamended, and the grand-ducal regulation governing grant, withdrawal and the royalty calculation was not obtained. The conclusion is well grounded in the enacted text and not confirmed against current consolidated law.

The Ministère de la Santé et de la Sécurité sociale page on buying medicines online, last modified 20 July 2026, states: four pharmacies in Luxembourg are approved for online sale, only medicines sans ordonnance may be sold online, and il n’est pas prévu d’autoriser la vente à distance de médicaments sur ordonnance.

That last clause is rare. Most regulators state the current rule; few state forward intent. Luxembourg has said not only that prescription distance selling is prohibited but that permitting it is not planned. For a planning horizon of any length, the domestic online prescription channel here is foreclosed.

The four approved pharmacies are Pharmacie Gillain in Dudelange, Pharmacie de Pétange, Pharmacie Steinfort and Pharmacie du Globe in Luxembourg City. Four licensed online sellers, over-the-counter only, is a very thin channel by any measure.

Three independent indications point the same way. The Agence eSanté lists only the Dossier de Soins Partagé and webservices among its services, with no ordonnance électronique. Luxembourg appears in neither Estonia’s nor Latvia’s list of cross-border e-prescription partners. And the CNS states, on reimbursement of purchases in Belgium, that une preuve de prescription électronique n’est pas acceptée par la CNS, because it has no legal value; a classic prescription is required.

That third point is the sharpest, because Belgium is where Luxembourg residents most often fill prescriptions and Belgium runs a heavily electronic system. The friction is live and current.

CNS dispensing rules add further constraints: one prescription per patient per consultation subject to exceptions, three months validity in principle, the last of successive dispensings within six months of the first, only the smallest pack covered where no treatment duration is stated, and no more than two boxes of the same medicine from one prescription without renewal.

Whether an online-only consultation may lawfully found a prescription could not be established. No rule authorising or prohibiting it was found. The practical friction is high regardless.

The CNS Liste positive valid from 1 August 2026 contains no entry for Wegovy or Saxenda. Obesity indications are not covered, so weight management is self-pay.

The diabetes picture is more interesting than usual, because the conditions differ sharply by product:

• Ozempic and Rybelsus: reimbursed at 100%, coded conditional coverage without prior agreement, restricted by condition AH to the treatment of type 2 diabetes, with the prescriber obliged to state the usage framework on the prescription. That last requirement is an explicit anti-off-label control aimed at obesity prescribing. Ozempic public prices run 101.00 to 101.30 euros per pen, 191.95 for the 1 mg eight-pack; Rybelsus 94.94 euros for thirty tablets.
• Mounjaro: reimbursed at 100% but requiring prior authorisation from the Contrôle médical de la sécurité sociale, a materially higher barrier. Prices 174.69 euros at 2.5 mg to 323.80 euros at 7.5 and 10 mg.
• Trulicity: no condition at all, which is an anomaly worth noting.

A cash-pay obesity offer in Luxembourg competes against a system that pays 100% for the same molecules the moment a diabetes diagnosis exists.

A Luxembourg resident may buy prescribed medicines anywhere in the EU, EEA or Switzerland, pay in full and claim back. But reimbursement follows only if the product is on the Liste positive, the milligram strength matches the list exactly, and the name matches the list. Those two matching conditions will defeat a great many cross-border purchases of differently packaged GLP-1 presentations.

Where a Belgian pharmacy retains the prescription a copy must be attached, and electronic proof is refused. Purchases outside the EU, EEA and Switzerland are entirely at the patient’s expense outside emergencies.